2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1934 Immunostart: Chemotherapy-free prephase using tafasitamab, retifanlimab, and rituximab (TRR), followed by trr with standard chemotherapy, for first-line treatment of aggressive B-cell lymphoma

Stephen Douglas Smith, MD, Paul S Martin, MD2, Chaitra Ujjani, MD3, Kikkeri N Naresh, MD, MBBS, FRCPath4, Vikram Raghunathan, MD5, Ryan C Lynch, MD6, Mengyang Di, MD, PhD7, Brian G Till, MD8, Mazyar Shadman, MD, MPH9, Qian Wu, PhD10, Jenna Voutsinas, MPH11, Jason Sasser12, Ajay Gopal, MD13
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutch at EvergreenHealth, Kirkland, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction: Standard first-line chemoimmunotherapy for aggressive B-cell lymphoma (BCL) is toxic, and fails to cure a proportion of patients (pts). Innovative study designs are needed to assess the efficacy and biological impact of novel therapies, with the eventual goal of replacing chemotherapy. We previously showed that anti-PD1 therapy is safe when added to RCHOP (with no relapses in pts with PDL-1 positive tumors), and targeting CD19 is effective in first-line DLCBL. (Smith B J Haem 2020, Lenz Lancet 2026). Building on this work, we developed Immunostart: a "window-of-opportunity" study testing prephase tafasitamab, retifanlimab (anti-PD1), and rituximab (TRR) for two cycles, then adding standard chemotherapy (CHOP or polaCHP). We present the primary efficacy and safety results of Immunostart for DLBCL, including variants and high-grade BCL.

Methods: Immunostart (NCT05455697) is a single-arm trial enrolling adult pts with previously untreated aggressive BCL. Pts received 21-day cycles of prephase TRR: weekly tafasitamab (12 mg/kg), retifanlimab once per cycle (375 mg flat dose), and rituximab once per cycle (375 mg/m²). Prephase is followed by combination therapy with TRR and standard CHOP or polaCHP for 4-6 cycles, all given q21 days, with end-of-treatment (EOT) response per Lugano criteria. The primary endpoint is safety, defined as dose-limiting toxicity (DLT) rate during the first three cycles (two prephase and one combination cycle), assessed separately for CHOP and polaCHP backbones. Secondary endpoints include complete metabolic response (CMR) after prephase, end-of-treatment (EOT) response, and progression-free survival (PFS). A Simon 2-stage minimax design was employed, defining a prephase CMR rate of 30% (6 pts or more) as promising for further study, with an initial sample size of 25 evaluable pts; an expansion cohort is underway to include at least 10 pts age 70 or older. Correlative studies include ctDNA analysis and research biopsies of FDG-avid persistent lesions after prephase.

Results: 26 pts were treated in the initial cohort; 1 was not evaluable for efficacy, after withdrawing during prephase after a grade 3 AE. The median age was 63 years (range, 27-70). Histology was diffuse large B-cell lymphoma (DLBCL) in 22, high-grade B-cell lymphoma (HGBCL) in 2, and T-cell histiocyte rich large B-cell lymphoma (THLBLCL) in 2. IPI was 3 or higher in 8/26 (31%), and 65% had advanced stage disease.  By Hans criteria, 6/22 (27%) had non-germinal center subtype.  Except for one patient who withdrew, all patients proceeded to the combination phase as planned. One DLT occurred with TRR-polaCHP, a fatal Grade 5 neutropenic sepsis event during the first combination cycle, and none in the TRR-CHOP group. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 15 (60%) of pts, including 9 pts during prephase therapy; SAE occurred in 12 pts. Infections occurred in 11/26 pts, mostly grade 1-2 (7 pts). Immune-related AEs (irAEs) occurred in 5 pts, including Grade 3 myocarditis (n=1), grade 3 neutropenic fever with rash (n=1), and grade 1-2 thyroid abnormalities in 3 pts. Infusion-related reactions occurred in all pts, but were all Grade 1-2.

After two cycles of TRR prephase, ORR was 15/25 (60%) including 7 CMR (28%), meeting the prespecified efficacy threshold.  Three additional pts with residual FDG-avid lesions after prephase (2PR, 1SD) had biopsies demonstrating an inflammatory infiltrate and no lymphoma (PET + biopsy-defined CR in 10/25 [40%]). At EOT, 19/25 (76%) achieved CMR (4 PR, 1 PD; and 1 grade 5 toxicity scored a nonresponder).  With median follow-up of 16.8 months, 12-month PFS and OS are 92% (82–100%). Two relapses occurred: 1 primary refractory DLBCL, and one 34 months after study start (both GCB subtype). Correlative ctDNA analysis is underway, and updated results will be presented.

Conclusions: Immunostart with prephase TRR demonstrates significant chemo-free activity in untreated LBCL, meeting our efficacy benchmark for further study. This immunotherapy-only window platform is feasible, without compromising the delivery of subsequent curative chemotherapy. Our findings suggest benefit of tafasitamab without lenalidomide in untreated aggressive BCL, and support continued development of immunotherapy-led frontline strategies to improve toxicity and cure rates for aggressive BCL.

Stephen Douglas Smith, MD: ADC Therapeutics, Astrazeneca, Beigene, Corvus Pharmaceuticals, Enterome, Genentech, Incyte Corporation, Kymera Therapeutics, Loxo Oncology, Pfizer Oncology, Viracta Therapeutics - Research Funding; Enterome - Research Funding; Natera - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Beigene, Natera - Consultancy (Includes expert testimony)